Ekaterina A. Khuzina
Research Subjects
Ekaterina A. Khuzina has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Evgenij G. Furman
Ye.A. Vagner Perm State Medical University
6 shared publications - Yulia S. Alieva
Academician Ye.A. Wagner Perm State Medical University
3 shared publications - M. S. Ponomareva
E.A. Vagner Perm State Medical University
2 shared publications E.I. Kondratyeva
Medical and Genetic Research Centre named after Academician N.P. Bochkov Moscow RF
1 shared publication- Elena Ivanovna Kondratieva
Research Centre for Medical Genetics, Moscow 115522, Russia
1 shared publication Elena Loshkova
Siberian State Medical University
1 shared publication
Latest Publications
- 19 September 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 15 (2) , 53-62
Current knowledge of bronchial asthma with low T2-inflammation in school-aged children (review)
Bronchial asthma in children is a heterogeneous disease; therefore, determination of the disease endotype is important for personalized therapy, overcoming refractoriness to bronchial asthma treatment, and selecting a targeted biologic drug. The endotype of the disease, which is not associated with eosinophilia and, therefore, characterized by an insufficient response to inhaled corticosteroids, may begin at school age. The prevalence of low T2-inflammatory bronchial asthma in school-aged children is poorly understood, but the evidence presented in this article supports the presence of this endotype. This endotype of bronchial asthma in children is characterized by clinical and pathogenetic features, including low degree of allergic sensitization, reduced level of total IgE, limited number of positive allergy tests, decreased concentration of nitric oxide in exhaled air and eosinophil content in blood. The role of neutrophils in the development and prognosis of bronchial asthma in children is currently insufficiently studied and defined, nevertheless, it is known that the neutrophilic type of inflammation is associated with a more severe course of the disease and inadequate control. It is important to emphasize the need for further research into the endotypes of bronchial asthma in children with the identification of novel biomarkers and molecular mechanisms underlying asthma with low T2-inflammation. This may further enable the achievement of control of bronchial asthma with different inflammatory endotypes.
- 19 September 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 15 (2) , 53-62
Current knowledge of bronchial asthma with low T2-inflammation in school-aged children (review)
Bronchial asthma in children is a heterogeneous disease; therefore, determination of the disease endotype is important for personalized therapy, overcoming refractoriness to bronchial asthma treatment, and selecting a targeted biologic drug. The endotype of the disease, which is not associated with eosinophilia and, therefore, characterized by an insufficient response to inhaled corticosteroids, may begin at school age. The prevalence of low T2-inflammatory bronchial asthma in school-aged children is poorly understood, but the evidence presented in this article supports the presence of this endotype. This endotype of bronchial asthma in children is characterized by clinical and pathogenetic features, including low degree of allergic sensitization, reduced level of total IgE, limited number of positive allergy tests, decreased concentration of nitric oxide in exhaled air and eosinophil content in blood. The role of neutrophils in the development and prognosis of bronchial asthma in children is currently insufficiently studied and defined, nevertheless, it is known that the neutrophilic type of inflammation is associated with a more severe course of the disease and inadequate control. It is important to emphasize the need for further research into the endotypes of bronchial asthma in children with the identification of novel biomarkers and molecular mechanisms underlying asthma with low T2-inflammation. This may further enable the achievement of control of bronchial asthma with different inflammatory endotypes.
- Open Access
- 5 June 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 92-99
Age-related features of the choice of inhalers in chilren and adolescents with bronchial asthma and other respiratory diseases
The inhalation way of drug delivery seems to be the most logical for respiratory diseases. However, the most important condition for the effectiveness of inhalation therapy in children and adolescents along with the correct choice of the active substance is the selection of the optimal device and adequate execution of the inspiratory maneuver. When prescribing therapy attention should be paid to the inhalation technique of a particular patient and also take into account the likelihood of side effects when using certain devices. The article provides data on factors affecting the pulmonary deposit of the drug, the internal resistance of various inhalers which have the greatest informativeness for choosing a device along with the assessment of the inspiratory flow rate developed by the patient. The most problematic aspects of drug delivery to the respiratory tract in children under 5 years of age and in patients with inadequate inhalation rate are analyzed. The principles of correct inhalation are discussed which are necessary to obtain an optimal respiratory fraction. It is known that the problem of synchronizing inhalation with the moment of receipt of the drug is the most important when using metered – dose aerosol inhalers. In children this problem can be solved by using a spacer or using nebulizers that convert the liquid form of the drug into an aerosol using compressor air. Individual selection of an inhaler depending on the abilities and preferences of the patient in some groups of patients can significantly increase the effectiveness of therapy without increasing the dose of medications. The article presents up-to-date data on digital inhaler systems and the possibilities of using electronic devices for monitoring and using the inhaler.
- 5 June 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 92-99
Open AccessAge-related features of the choice of inhalers in chilren and adolescents with bronchial asthma and other respiratory diseases
The inhalation way of drug delivery seems to be the most logical for respiratory diseases. However, the most important condition for the effectiveness of inhalation therapy in children and adolescents along with the correct choice of the active substance is the selection of the optimal device and adequate execution of the inspiratory maneuver. When prescribing therapy attention should be paid to the inhalation technique of a particular patient and also take into account the likelihood of side effects when using certain devices. The article provides data on factors affecting the pulmonary deposit of the drug, the internal resistance of various inhalers which have the greatest informativeness for choosing a device along with the assessment of the inspiratory flow rate developed by the patient. The most problematic aspects of drug delivery to the respiratory tract in children under 5 years of age and in patients with inadequate inhalation rate are analyzed. The principles of correct inhalation are discussed which are necessary to obtain an optimal respiratory fraction. It is known that the problem of synchronizing inhalation with the moment of receipt of the drug is the most important when using metered – dose aerosol inhalers. In children this problem can be solved by using a spacer or using nebulizers that convert the liquid form of the drug into an aerosol using compressor air. Individual selection of an inhaler depending on the abilities and preferences of the patient in some groups of patients can significantly increase the effectiveness of therapy without increasing the dose of medications. The article presents up-to-date data on digital inhaler systems and the possibilities of using electronic devices for monitoring and using the inhaler.
- 15 January 2024
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 41 (1) , 59-72
Association of polymorphic variants of HHIP, ADRB2 and IL-33 genes with clinical manifestations of bronchial asthma in children
Objective. To study the association of polymorphic variants HHIP, ADRB2 and IL-33 genes with phenotypes of clinical course of bronchial asthma in children and effective treatment. Materials and methods. 90 patients aged from 5 to 17 with the diagnosis of bronchial asthma were included in the investigation. Diagnostic procedures were carried out in all the patients. They included the study of genetic polymorphism of HHIP, ADRB2 and IL-33 genes to establish the association with the clinical phenotypes, findings of laboratory and instrumental study determining the course of bronchial asthma and the degree of its control. Results. The study of polymorphism of HHIP, ADRB2 and IL-33 genes in children with bronchial asthma with different phenotypes of the disease revealed the association of genetic polymorphism with the severity of course of the disease as well as concomitant diseases. It was determined that allele T of genetic variant rs12504628 (TC) of HHIP gene reduces the risk of a severe course of BA. Its protective role in the development of drug allergy was also proved. Genotype AA of ADRB2 gene is associated with reduced risks of the development of congenital defects of the tracheobronchial tree in BA. Polymorphic variants in the 4th and 6th exon of IL-33 gene are more frequently associated with moderate and severe course of asthma and base substitution in the 4th and 6th exon are associated with the severe course. Conclusions. Associations of polymorphic variants of HHIP, ADRB2 and IL-33 genes with clinical manifestations of BA in children are determined in this study. They can be considered in a personalized monitoring of the patients and can help to control the disease totally.
- 15 January 2024
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 41 (1) , 59-72
Association of polymorphic variants of HHIP, ADRB2 and IL-33 genes with clinical manifestations of bronchial asthma in children
Objective. To study the association of polymorphic variants HHIP, ADRB2 and IL-33 genes with phenotypes of clinical course of bronchial asthma in children and effective treatment. Materials and methods. 90 patients aged from 5 to 17 with the diagnosis of bronchial asthma were included in the investigation. Diagnostic procedures were carried out in all the patients. They included the study of genetic polymorphism of HHIP, ADRB2 and IL-33 genes to establish the association with the clinical phenotypes, findings of laboratory and instrumental study determining the course of bronchial asthma and the degree of its control. Results. The study of polymorphism of HHIP, ADRB2 and IL-33 genes in children with bronchial asthma with different phenotypes of the disease revealed the association of genetic polymorphism with the severity of course of the disease as well as concomitant diseases. It was determined that allele T of genetic variant rs12504628 (TC) of HHIP gene reduces the risk of a severe course of BA. Its protective role in the development of drug allergy was also proved. Genotype AA of ADRB2 gene is associated with reduced risks of the development of congenital defects of the tracheobronchial tree in BA. Polymorphic variants in the 4th and 6th exon of IL-33 gene are more frequently associated with moderate and severe course of asthma and base substitution in the 4th and 6th exon are associated with the severe course. Conclusions. Associations of polymorphic variants of HHIP, ADRB2 and IL-33 genes with clinical manifestations of BA in children are determined in this study. They can be considered in a personalized monitoring of the patients and can help to control the disease totally.
- Open Access
Association of Polymorphic Variants of HHIP, ADRB2 and IL-33 Genes with Clinical Manifestations of Bronchial Asthma in Children
Studying the contribution of genetic mechanisms to the development of bronchial asthma (BA) is to look for associations of the disease and its phenotypes with polymorphic markers of candidate genes. Objective: To investigate the association of polymorphic variants of HHIP, ADRB2 and IL-33 genes with the phenotypes of clinical course of BA in children and the effectiveness of therapy of the disease Patients and methods: A cohort single-center study of 90 bronchial asthma patients aged 5 to 17 years with an established diagnosis of bronchial asthma of varying degree of severity and control was conducted. The allele and genotype frequencies of polymorphic loci of the following genes were studied: rs12551256-A and rs146597587-G of IL-33 gene; rs12504628 of HHIP gene and ARG16GLY rs1042713 of ADRB2 gene in 90 BA patients with regard to the severity and control of the disease. In children with severe BA, as well as in children with poorly controlled/uncontrolled asthma (n=26), sequencing of the entire coding sequence of the IL-33 gene located on the 9th chromosome in the 9p24.1 region was additionally performed (search for mutations in 9 exons). Results: Comparison of genetic markers in patients with severe BA (tBA) and non-severe BA (nBA) revealed a reduced risk of severe disease realization among those carrying the TT genotype (OR=0.221 (95% CI: 0.059-0.828; χ2=5.759; p=0.056)) and the T allele (OR=0.491 (95% CI: 0.190-1.269; χ2=4.270; p=0.039)) of the studied genetic variant rs12504628 (T>C) of the HHIP gene, the frequency of the CC genotype in severe BA was 64%, versus 28% in nonsevere BA, and the C allele 77% versus 52%.Comparison of genetic markers in patients with a combination of atopic dermatitis (AtD) and bronchial asthma (BA+AtD) and BA without AtD (BA without AtD) revealed an increased risk of combining asthma and dermatitis among individuals carrying the TT genotype (OR=2.875 (95% CI: 1.130-7.316; χ2=5.751; p=0.056)) of genetic variant rs12504628 (T>C) of the HHIP gene. Sequencing and exome analysis of the IL-33 gene showed a statistically significant positive association between the frequency of lesions in exons 4 (r=0.417; p=0.034) and 6 (r=0.593; p=0.001) on the one hand and the severity of BA on the other. Nucleotide substitutions in these exons were found to be more frequently associated with the severe course of bronchial asthma. Conclusion: It was shown that TT genotype of genetic variant rs12504628 (T>C) of HHIP gene reduces the risk of severe BA, but increases the risk of atopic dermatitis combined with BA by 2.8 times. The CC+ST genotype of the HHIP gene increases the risk of drug allergy against the background of BA by 2.9 times. Polymorphic variants in exons 4 and 6 of the IL-33 gene are more often combined with moderate and severe asthma, and nucleotide substitutions in exons 4 and 6 are associated with a severe course of BA.
Open AccessAssociation of Polymorphic Variants of HHIP, ADRB2 and IL-33 Genes with Clinical Manifestations of Bronchial Asthma in Children
Studying the contribution of genetic mechanisms to the development of bronchial asthma (BA) is to look for associations of the disease and its phenotypes with polymorphic markers of candidate genes. Objective: To investigate the association of polymorphic variants of HHIP, ADRB2 and IL-33 genes with the phenotypes of clinical course of BA in children and the effectiveness of therapy of the disease Patients and methods: A cohort single-center study of 90 bronchial asthma patients aged 5 to 17 years with an established diagnosis of bronchial asthma of varying degree of severity and control was conducted. The allele and genotype frequencies of polymorphic loci of the following genes were studied: rs12551256-A and rs146597587-G of IL-33 gene; rs12504628 of HHIP gene and ARG16GLY rs1042713 of ADRB2 gene in 90 BA patients with regard to the severity and control of the disease. In children with severe BA, as well as in children with poorly controlled/uncontrolled asthma (n=26), sequencing of the entire coding sequence of the IL-33 gene located on the 9th chromosome in the 9p24.1 region was additionally performed (search for mutations in 9 exons). Results: Comparison of genetic markers in patients with severe BA (tBA) and non-severe BA (nBA) revealed a reduced risk of severe disease realization among those carrying the TT genotype (OR=0.221 (95% CI: 0.059-0.828; χ2=5.759; p=0.056)) and the T allele (OR=0.491 (95% CI: 0.190-1.269; χ2=4.270; p=0.039)) of the studied genetic variant rs12504628 (T>C) of the HHIP gene, the frequency of the CC genotype in severe BA was 64%, versus 28% in nonsevere BA, and the C allele 77% versus 52%.Comparison of genetic markers in patients with a combination of atopic dermatitis (AtD) and bronchial asthma (BA+AtD) and BA without AtD (BA without AtD) revealed an increased risk of combining asthma and dermatitis among individuals carrying the TT genotype (OR=2.875 (95% CI: 1.130-7.316; χ2=5.751; p=0.056)) of genetic variant rs12504628 (T>C) of the HHIP gene. Sequencing and exome analysis of the IL-33 gene showed a statistically significant positive association between the frequency of lesions in exons 4 (r=0.417; p=0.034) and 6 (r=0.593; p=0.001) on the one hand and the severity of BA on the other. Nucleotide substitutions in these exons were found to be more frequently associated with the severe course of bronchial asthma. Conclusion: It was shown that TT genotype of genetic variant rs12504628 (T>C) of HHIP gene reduces the risk of severe BA, but increases the risk of atopic dermatitis combined with BA by 2.8 times. The CC+ST genotype of the HHIP gene increases the risk of drug allergy against the background of BA by 2.9 times. Polymorphic variants in exons 4 and 6 of the IL-33 gene are more often combined with moderate and severe asthma, and nucleotide substitutions in exons 4 and 6 are associated with a severe course of BA.
- 13 October 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (5)
LUNG DAMAGE ASSOCIATED WITH THE USE OF ELECTRONIC CIGARETTES AND VAPING IN CHILDREN AND ADOLESCENTS
Electronic consumer products (devices, systems) made to delivering of nicotine-containing products are very popular among teenagers and children nowadays. There is a large amount of scientific research data and clinical cases describing the negative effects of electronic cigarettes on the respiratory system, primarily on the lungs. The components of e-liquids can cause inflammation, oxidative stress, infectious complications and disrupt the genetic apparatus of cells in the mucous membrane of the respiratory tract. Awareness and vigilance regarding the possibility of lung injury in heavy e-cigarette users is extremely important because, unfortunately, there are currently no effective ways to limit the distribution and the use of such kind of devices. The article represents bibliographical data on the pathogenesis, diagnostic capabilities and approaches to treatment of lung injuries associated with vaping.
- 13 October 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (5)
LUNG DAMAGE ASSOCIATED WITH THE USE OF ELECTRONIC CIGARETTES AND VAPING IN CHILDREN AND ADOLESCENTS
Electronic consumer products (devices, systems) made to delivering of nicotine-containing products are very popular among teenagers and children nowadays. There is a large amount of scientific research data and clinical cases describing the negative effects of electronic cigarettes on the respiratory system, primarily on the lungs. The components of e-liquids can cause inflammation, oxidative stress, infectious complications and disrupt the genetic apparatus of cells in the mucous membrane of the respiratory tract. Awareness and vigilance regarding the possibility of lung injury in heavy e-cigarette users is extremely important because, unfortunately, there are currently no effective ways to limit the distribution and the use of such kind of devices. The article represents bibliographical data on the pathogenesis, diagnostic capabilities and approaches to treatment of lung injuries associated with vaping.
- Open Access
- 1 January 2020
- Published by NP Rusmedical Group in Doctor.Ru
- Vol. 19 (10)
Bronchial Asthma in Children Amidst the Novel Coronavirus Infection
Objective of the Review: to present current information on monitoring and therapy of bronchial asthma (BA) in children amidst the novel coronavirus infection COVID-19. Key Points. There is no evidence that controlled BA increases the risk of SARS-CoV-2 infection or leads to more severe COVID-19. Inhaled glucocorticosteroids (IGCS) to manage BA inhibit gene expression of major SARS-CoV-2 target receptors. Anti-inflammatory BA therapy, primarily IGCS, should not be discontinued until BA is controlled, thus mitigating the risk of unfavourable course of COVID-19. Nebuliser therapy at home remains the preferred treatment in pre-school children with BA. Conclusion. Amidst the novel coronavirus infection COVID-19, children with BA should receive individualised therapy depending on disease severity and rate of disease control. Keywords: bronchial asthma, children, novel coronavirus infection COVID-19.
- 1 January 2020
- Published by NP Rusmedical Group in Doctor.Ru
- Vol. 19 (10)
Open AccessBronchial Asthma in Children Amidst the Novel Coronavirus Infection
Objective of the Review: to present current information on monitoring and therapy of bronchial asthma (BA) in children amidst the novel coronavirus infection COVID-19. Key Points. There is no evidence that controlled BA increases the risk of SARS-CoV-2 infection or leads to more severe COVID-19. Inhaled glucocorticosteroids (IGCS) to manage BA inhibit gene expression of major SARS-CoV-2 target receptors. Anti-inflammatory BA therapy, primarily IGCS, should not be discontinued until BA is controlled, thus mitigating the risk of unfavourable course of COVID-19. Nebuliser therapy at home remains the preferred treatment in pre-school children with BA. Conclusion. Amidst the novel coronavirus infection COVID-19, children with BA should receive individualised therapy depending on disease severity and rate of disease control. Keywords: bronchial asthma, children, novel coronavirus infection COVID-19.